feedback

Course Director

Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, MACP, FASCO

University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Faculty

Philip Kantoff
Philip Kantoff, MD

Memorial Sloan Kettering Cancer Center
Weill Cornell Medical School
New York, New York

Charles J. Ryan
Charles J. Ryan, MD

University of Minnesota
Minneapolis, Minnesota

Evan Y. Yu
Evan Y. Yu, MD

University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, Washington

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2019-Jul-16
Expiration Date:2020-Jul-15
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

The therapeutic landscape for prostate cancer has evolved rapidly in recent years, and research endeavors continue to expand treatment options, with significant implications for patients with early-stage and advanced disease. In addition to the approval of multiple second-generation anti-androgen therapies in nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer, current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. When managing patients with prostate cancer, clinicians must consider established, newly approved, and emerging therapies throughout the disease continuum, as well as individual patient-, tumor-, and treatment-related factors. Questions that frequently arise include: What is the impact of using anti-androgen therapies earlier in the treatment plan? What is the ideal way to sequence therapies in different disease settings? How should therapy be personalized to ensure that each patient with prostate cancer receives the right treatment?

Answers to these and other thought-provoking queries are provided by a panel of prostate cancer experts in this PeerView Talks CME-certified on-demand activity based on a recent live symposium at the American Society of Clinical Oncology Annual Meeting 2019 (ASCO 2019) in Chicago, Illinois. Utilizing an innovative educational design, the experts relate engaging patient stories and link them to practical clinical considerations, enabling learners to better connect evidence to everyday practice.

Upon completion of this activity, participants should be better able to:
  • Discuss the clinical evidence, latest guidelines, and expert recommendations for selection and sequencing of hormonal, anti-androgen, cytotoxic, bone-directed, molecularly targeted, and other therapies throughout the disease continuum for patients with hormone-naïve, hormone-sensitive, or castration-resistant, nonmetastatic, and metastatic prostate cancer
  • Develop personalized, evidence-based treatment plans for patients with early-stage and advanced prostate cancer with considerations of tumor-, patient-, and treatment-related factors
  • Summarize current and planned clinical trials assessing novel strategies with potential to improve outcomes in different prostate cancer settings

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with prostate cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 16, 2019 - July 15, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Robert Dreicer, MD, MS, MACP, FASCO
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma US, Inc.; AstraZeneca; Eisai Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer, Inc.
Grant/Research Support from Endocytic; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.

Faculty

Philip Kantoff, MD
Chairman of Medicine
George J. Bosl Professor of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical School
New York, New York

Philip Kantoff, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bavarian Nordic; DRGT Ltd.; GE Healthcare; Janssen Pharmaceuticals, Inc.; New England Research Institutes, Inc.; OncoCell MDX; Progenity, Inc.; Sanofi; Seer Biosciences; Tarveda Therapeutics (previously Blend); and Thermo Fisher.
Data Safety Monitoring Board in Genentech, Inc./F. Hoffmann-La Roche Ltd and Merck & Co., Inc.
Other financial interest/relationship with Context Therapeutics in the form of investment interest and Member of Company Board.
Investment interest from DRGT Ltd.; Placon; Seer Biosciences; and Tarveda Therapeutics (previously Blend).

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Charles J. Ryan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer Corporation; Janssen Pharmaceuticals, Inc.; and Sanofi Genzyme.
Grant/Research Support from Clovis Oncology.

Evan Y. Yu, MD
Professor, Department of Medical Oncology
University of Washington School of Medicine
Medical Director, Clinical Research Support
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Evan Y. Yu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Bayer Corporation; Dendreon Pharmaceuticals LLC.; Janssen Pharmaceuticals, Inc.; Pharmacyclics LLC; Merck & Co., Inc.; QED Therapeutics; and Seattle Genetics, Inc.
Grant/Research Support from Bayer Corporation; Daiichi Sankyo Company, Limited.; Dendreon Pharmaceuticals LLC.; Merck & Co., Inc.; Seattle Genetics, Inc.; and Taiho Oncology, Inc.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # 6497-20-T.

Providership


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Clovis Oncology, Inc., Janssen Biotech, Inc., Merck & Co., Inc., and Sanofi Genzyme.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.